.jpg)
Thursday, 12 March 2009
Fiddaman went cold turkey - his choice, his brain damage, he was warned but he wouldn't listen !
He outlined his own experience of withdrawing over a period of 21 months. The liquid, administered through a syringe, helped that process, though – for him – not even tapering took him beyond the point where he felt he had to "go cold turkey". He did that because he did not want the drug to continue to have a hold over him.
Fiddaman "produced copies of the Patient Information Leaflet (PIL) for Seroxat" - a drug that only accounts for 5% of UK antidepressant use
2. He produced copies of the Patient Information Leaflet (PIL) for Seroxat in which he had highlighted the 32 places where patient
Baseball bat waving thug, kneecapper & stun gun seeker Fiddaman - tries to pin it on Seroxat
7 - and exemplified that by relating his feelings of wanting to "rip the shop apart" if it turned out that they were out of stock.
http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON025700&RevisionSelectionMethod=Latest
http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON025700&RevisionSelectionMethod=Latest
7. During withdrawal he experienced severe "zaps" in his brain - Fiddaman was taking Prothiaden Seroxat & Tramadol
7. During withdrawal he experienced severe "zaps" in his brain. He described his dependence on the drug as an addiction,
http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON025700&RevisionSelectionMethod=Latest
http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON025700&RevisionSelectionMethod=Latest
Bob Fiddaman's meeting with top Civil servants @ the MHRA
http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON025700&RevisionSelectionMethod=Latest
http://www.mhra.gov.uk/Yourviews/Consultations/Medicinesconsultations/Othermedicinesconsultations/Discussionswithstakeholders/CON025699
Guidance on the Management of Withdrawal from
Seroxat (Paroxetine) and Other SSRIs
Notes of a meeting held at MHRA on 2 September 2008
Present:
Robert (Bob) Fiddaman (RF), Campaigner, Author of Seroxat Sufferers Blog
Prof. Kent Woods (KW), Chief Executive, MHRA
Sarah Morgan (SM), Head of Pharmacovigilance Risk Management, MHRA
John Watkins (JW), Communication Manager, MHRA, acting as secretary
1. RF said he would like to discuss problems of withdrawing from Seroxat. He said that though his concerns centred around Seroxat, he recognised that other SSRIs posed similar problems which ought also to be addressed.
2. He produced copies of the Patient Information Leaflet (PIL) for Seroxat in which he had highlighted the 32 places where patients were told to talk with their doctor about various issues. He felt that too much of an onus was put on doctors, many of whom did not know enough about withdrawal problems and their management.
3. In answer to a question from KW, RF agreed that the focus of the meeting should be on the information going to doctors and perhaps also on their training.
4. KW noted that doctors do not generally refer to the PILs, nor indeed to the similar but more technical Summaries of Product Characteristics (SPCs). Instead, they use the British National Formulary (BNF), revised twice each year, and guidance produced by NICE. The NICE guidance on the management of depression was currently being revised; a draft is due to go out for public consultation in December 2008 with a view to publication in June 2009.
5. He emphasised that MHRA controls neither the BNF nor NICE in any of the matters they cover, but the Agency can and does make suggestions to both organisations about the information they provide.
6. RF illustrated the practical problems encountered by patients in withdrawing. He offered each of the others a jelly baby and asked them to bite off one-third. No problem. He then produced some Tic-Tacs (mints). It was immediately acknowledged that biting off a third was very difficult. Likewise with a Seroxat tablet, said RF. The liquid preparation was much better suited to dose tapering but doctors seemed largely unaware of it. He outlined his own experience of withdrawing over a period of 21 months. The liquid, administered through a syringe, helped that process, though – for him – not even tapering took him beyond the point where he felt he had to "go cold turkey". He did that because he did not want the drug to continue to have a hold over him.
7. During withdrawal he experienced severe "zaps" in his brain. He described his dependence on the drug as an addiction, and exemplified that by relating his feelings of wanting to "rip the shop apart" if it turned out that they were out of stock.
8. KW noted that the term "addiction" ought to be reserved for circumstances which typically entailed cravings leading to increase in dosage, but suggested it was less important to argue about terminology than to acknowledge, as he did, that there are significant problems associated with withdrawal; the issue was how best to manage withdrawal. He noted that, as with benzodiazepines, those SSRIs which both act and disappear more quickly are more likely to pose problems with withdrawal. He did not know whether a switch to slower acting SSRIs had been researched as a potential solution, as it had proved to be for benzodiazepines.
http://www.mhra.gov.uk/Yourviews/Consultations/Medicinesconsultations/Othermedicinesconsultations/Discussionswithstakeholders/CON025699
Guidance on the Management of Withdrawal from
Seroxat (Paroxetine) and Other SSRIs
Notes of a meeting held at MHRA on 2 September 2008
Present:
Robert (Bob) Fiddaman (RF), Campaigner, Author of Seroxat Sufferers Blog
Prof. Kent Woods (KW), Chief Executive, MHRA
Sarah Morgan (SM), Head of Pharmacovigilance Risk Management, MHRA
John Watkins (JW), Communication Manager, MHRA, acting as secretary
1. RF said he would like to discuss problems of withdrawing from Seroxat. He said that though his concerns centred around Seroxat, he recognised that other SSRIs posed similar problems which ought also to be addressed.
2. He produced copies of the Patient Information Leaflet (PIL) for Seroxat in which he had highlighted the 32 places where patients were told to talk with their doctor about various issues. He felt that too much of an onus was put on doctors, many of whom did not know enough about withdrawal problems and their management.
3. In answer to a question from KW, RF agreed that the focus of the meeting should be on the information going to doctors and perhaps also on their training.
4. KW noted that doctors do not generally refer to the PILs, nor indeed to the similar but more technical Summaries of Product Characteristics (SPCs). Instead, they use the British National Formulary (BNF), revised twice each year, and guidance produced by NICE. The NICE guidance on the management of depression was currently being revised; a draft is due to go out for public consultation in December 2008 with a view to publication in June 2009.
5. He emphasised that MHRA controls neither the BNF nor NICE in any of the matters they cover, but the Agency can and does make suggestions to both organisations about the information they provide.
6. RF illustrated the practical problems encountered by patients in withdrawing. He offered each of the others a jelly baby and asked them to bite off one-third. No problem. He then produced some Tic-Tacs (mints). It was immediately acknowledged that biting off a third was very difficult. Likewise with a Seroxat tablet, said RF. The liquid preparation was much better suited to dose tapering but doctors seemed largely unaware of it. He outlined his own experience of withdrawing over a period of 21 months. The liquid, administered through a syringe, helped that process, though – for him – not even tapering took him beyond the point where he felt he had to "go cold turkey". He did that because he did not want the drug to continue to have a hold over him.
7. During withdrawal he experienced severe "zaps" in his brain. He described his dependence on the drug as an addiction, and exemplified that by relating his feelings of wanting to "rip the shop apart" if it turned out that they were out of stock.
8. KW noted that the term "addiction" ought to be reserved for circumstances which typically entailed cravings leading to increase in dosage, but suggested it was less important to argue about terminology than to acknowledge, as he did, that there are significant problems associated with withdrawal; the issue was how best to manage withdrawal. He noted that, as with benzodiazepines, those SSRIs which both act and disappear more quickly are more likely to pose problems with withdrawal. He did not know whether a switch to slower acting SSRIs had been researched as a potential solution, as it had proved to be for benzodiazepines.
Seroxat only 5.2% of UK AD consumption where Total Ad's = 33.839 mill, Total paroxetine = 1.765 mill
Total for BNF : 4 . 3 Antidepressant Drugs 33,839.6
Total for chemical entity : Paroxetine Hydrochloride 1,765.9
source of info - see page 121 of 619 the pdf file provided by the O.N.S
http://www.ic.nhs.uk/webfiles/publications/PCA%20publication/PCA%202007%20complete%20V2.pdf
see also -
http://www.network54.com/Forum/281849/message/1236804048/Prescription+Cost+Analysis+2007+-+published+April+2008
Total for chemical entity : Paroxetine Hydrochloride 1,765.9
source of info - see page 121 of 619 the pdf file provided by the O.N.S
http://www.ic.nhs.uk/webfiles/publications/PCA%20publication/PCA%202007%20complete%20V2.pdf
see also -
http://www.network54.com/Forum/281849/message/1236804048/Prescription+Cost+Analysis+2007+-+published+April+2008
from - Prescription Cost Analysis 2007 - let's compare actual dispensing of various antidepressants in the real world
Total for chemical entity : Citalopram Hydrobromide 7,830.7
Total for chemical entity : Fluoxetine Hydrochloride 5,045.7
Total for chemical entity : Venlafaxine Hydrochloride 2,274.7
Total for chemical entity : Sertraline Hydrochloride 2,032.8
Total for chemical entity : Paroxetine Hydrochloride 1,765.9
Total for chemical entity : Escitalopram 1,373.9
Total for chemical entity : Duloxetine Hydrochloride 267.3
Total for chemical entity : Fluvoxamine Maleate 29.9
source of info - see page 121 of 619 the pdf file provided by the O.N.S
http://www.ic.nhs.uk/webfiles/publications/PCA%20publication/PCA%202007%20complete%20V2.pdf
Total for BNF : 4 . 3 Antidepressant Drugs 33,839.6
Total for chemical entity : Fluoxetine Hydrochloride 5,045.7
Total for chemical entity : Venlafaxine Hydrochloride 2,274.7
Total for chemical entity : Sertraline Hydrochloride 2,032.8
Total for chemical entity : Paroxetine Hydrochloride 1,765.9
Total for chemical entity : Escitalopram 1,373.9
Total for chemical entity : Duloxetine Hydrochloride 267.3
Total for chemical entity : Fluvoxamine Maleate 29.9
source of info - see page 121 of 619 the pdf file provided by the O.N.S
http://www.ic.nhs.uk/webfiles/publications/PCA%20publication/PCA%202007%20complete%20V2.pdf
Total for BNF : 4 . 3 Antidepressant Drugs 33,839.6
Wednesday, 11 March 2009
JUST CONCERTS @ £4.40 PER DISC from Robert Fiddaman 26 Gorsly Piece. Quinton Birmingham
JUST CONCERTS @ £4.40 PER DISC from Robert Fiddaman (benefit thief) 26 Gorsly Piece. Quinton Birmingham
source - http://www.webspawner.com/users/ballbreaker/
JUST CONCERTS
--------------------------------------------------------------------------------
TRADE LIKE FOR LIKE THE PREFERRED METHOD. IF YOU WANT TO BUY BECAUSE YOU HAVE NOTHING TO TRADE THEN THE PRICES ARE AS FOLLOWS:
£4.40 PER DISC
£5.40 FOR DOUBLE DISC
£ 5.90 FOR TRIPLE DISC
source - http://www.webspawner.com/users/ballbreaker/
JUST CONCERTS
--------------------------------------------------------------------------------
TRADE LIKE FOR LIKE THE PREFERRED METHOD. IF YOU WANT TO BUY BECAUSE YOU HAVE NOTHING TO TRADE THEN THE PRICES ARE AS FOLLOWS:
£4.40 PER DISC
£5.40 FOR DOUBLE DISC
£ 5.90 FOR TRIPLE DISC
BBC NEWS | Politics | MPs urge action on cinema filming
BBC NEWS | Politics | MPs urge action on cinema filming: "MPs urge action on cinema filming
Cinemas have fitted devices to detect customers' camcorders
The government is being urged to make the use of video cameras in cinemas a criminal offence.
Eleven MPs have signed a Commons motion claiming the practice is to blame for about 90% of fake DVDs on sale."
Cinemas have fitted devices to detect customers' camcorders
The government is being urged to make the use of video cameras in cinemas a criminal offence.
Eleven MPs have signed a Commons motion claiming the practice is to blame for about 90% of fake DVDs on sale."
Subscribe to:
Posts (Atom)